Ivermectin for Cancer: Dr. William Makis Protocol Explained (2026 Guide)

By Editorial Team
A balanced, evidence-informed guide for cancer patients and caregivers exploring ivermectin as a repurposed therapy — what the research shows, what it doesn't, and how to proceed safely.

Contents

  1. Who Is Dr. William Makis?
  2. How Ivermectin May Work Against Cancer
  3. The Core Protocols (2025–2026)
  4. What the Research Actually Shows
  5. Reported Patient Outcomes
  6. Risks, Side Effects & Drug Interactions
  7. How to Access Ivermectin Safely
  8. Frequently Asked Questions
  9. Key Takeaways
Medical Disclaimer:

This article is for educational purposes only and does not constitute medical advice. Ivermectin used in cancer care is off-label and investigational. The evidence base is still developing. Do not start, stop, or change any treatment without guidance from a licensed physician who knows your full medical history. Individual outcomes vary significantly.


1. Who Is Dr. William Makis?

Dr. William Makis is a Canadian-trained physician with a background in nuclear medicine and radiology (McGill University, 110+ peer-reviewed publications in imaging and oncology). Since 2023, he has been publicly documenting the use of repurposed antiparasitic drugs — primarily high-dose ivermectin combined with benzimidazoles — for cancer patients who have not responded to, or have declined, conventional treatments.

He shares patient cases and dosing guidance through his Substack publication and on X (formerly Twitter, @MakisMD). His approach draws from the growing body of preclinical research on ivermectin's potential anti-tumor mechanisms, as well as an emerging set of real-world observational reports.

Important Context:

Dr. Makis clinical claims are based on anecdotal patient reports and preclinical research, not completed randomized controlled trials. His work should be understood as hypothesis-generating, not practice-defining. That said, he is one of the most active practitioners publicly documenting this area, and his protocols are being followed by many patients globally.

2. How Ivermectin May Work Against Cancer

Ivermectin was developed as an antiparasitic drug and has a well-established safety record at standard doses. Researchers have identified several mechanisms by which it may interfere with cancer cell biology:
  • Microtubule disruptionBlocks the structural scaffolding cancer cells need to dividePreclinical
  • P-glycoprotein inhibitionMay reduce drug resistance in tumors, potentially making other treatments more effectivePreclinical
  • WNT/β-catenin pathway suppressionInterferes with a signaling pathway involved in cancer stem cell survival and tumor growthPreclinical
  • Mitochondrial dysfunction in tumorsSelectively impairs energy production in cancer cells, which rely heavily on mitochondrial metabolismEarly/in vitro
  • Immune modulationMay enhance the body's anti-tumor immune response, though this mechanism is the least well-characterisedTheoretical
In a comprehensive 2020 study (Juarez et al.), ivermectin was tested against 28 cancer cell lines. The most responsive were ovarian, breast, glioblastoma, lung, and colon cancers. It is important to note that cell line results do not automatically translate to human outcomes — many drugs that work in a lab do not work in patients, or require very different doses.

3. The Core Protocols (2025–2026)

The following protocols are based on Dr. Makis's publicly shared guidance as of early 2026. These are presented for informational purposes. None of these should be self-administered. Dosages, combinations, and duration must be individualized by a physician with access to your labs, imaging, and medical history.
⚠ Safety Note on DosingStandard approved ivermectin doses for parasitic infection are approximately 0.2 mg/kg as a single dose. The doses described below are significantly higher and are off-label. Continuous high-dose ivermectin carries real risks (see Section 6). Liver function, kidney function, and drug interactions must be monitored regularly by a physician.

Protocol 1 — Standard (Most Common Cancers)

Applicable Cancer Types

Breast, colon, lung, prostate, melanoma, renal, gastric

Ivermectin Dose

1.0 mg/kg/day, taken daily with a fatty meal for absorption

Combination Partners
  • Fenbendazole 444–1000 mg/day or Mebendazole 1000 mg/day
  • Berberine 500 mg, 2–3× daily
  • CBD oil 100 mg/day
Suggested Duration

Minimum 3–6 months, with regular physician monitoring

Protocol 2 — Aggressive / High-Grade Cancers

Applicable Cancer Types

Lymphoma, leukemia, pancreatic, GBM, sarcoma, triple-negative breast

Ivermectin Dose

1.5–2.0 mg/kg/day — only under active physician supervision

Combination Partners
  • Fenbendazole 1000 mg/day + Mebendazole 1000–1500 mg/day
  • Methylene Blue 50–100 mg/day
  • High-dose Berberine
Suggested Duration

Daily until confirmed response, then taper under physician guidance

Protocol 3 — Low-Dose Ivermectin + High-Dose Benzimidazole

Applicable Cancer Types

Ovarian, uterine, some breast cancers (especially where high ivermectin is not tolerated)

Ivermectin Dose

0.5–1.0 mg/kg/day

Combination Partners
  • Fenbendazole 1000–2222 mg/day (3 days on / 4 off, or continuous)
  • CBD/THC oils, Berberine, Liposomal Curcumin
Suggested Duration

6–12 months minimum with regular labs

Protocol 4 — Maintenance / Remission

Applicable Cancer Types

All cancer types after achieving No Evidence of Disease (NED)

Ivermectin Dose

0.5–1.0 mg/kg, 3–5 days per week only

Combination Partners
  • Fenbendazole 444 mg/day or Mebendazole 500 mg/day
  • Berberine, Vitamin D 10,000–20,000 IU, Liposomal Curcumin
Suggested Duration

Minimum 1–2 years; indefinite based on clinical picture

General Protocol Rules (Per Dr. Makis)

  • Take ivermectin with a high-fat meal to significantly improve absorption
  • Use pharmaceutical-grade 12 mg human tablets only — not veterinary formulations
  • Monitor liver and kidney function every 4–6 weeks
  • Intermittent fasting or a ketogenic diet is recommended alongside for metabolic synergy
  • Topical DMSO application over accessible tumor sites is used by some patients.

4. What the Research Actually Shows

It is important for patients and caregivers to understand the current state of evidence — both its promise and its limitations.
  • Juarez et al. (2020) — 28 Cancer Cell LinesPreclinical

    Ivermectin showed anti-tumor activity across multiple cancer types at 2 mg/kg equivalent doses in vitro. Most responsive: ovarian, breast, glioblastoma, lung, and colon cancers.

  • Mebendazole RCT — Stage 4 Colorectal Cancer (Life Sciences, 2022)Phase 2 RCT

    Adding mebendazole to standard chemo improved 12-week overall response rate (65% vs 10%) and progression-free survival. This is the strongest human trial in this space.

  • EClinicalMedicine (2022) — Mebendazole + Temozolomide in Brain CancerPhase 1

    Encouraging safety and signal data in high-grade glioma. Not powered for efficacy conclusions, but tolerability was acceptable.

  • Hulscher et al. (April 2026) — 197-Patient Observational CohortObservational

    84.4% clinical benefit rate reported: NED 32.8%, tumor regression 15.6%, stable disease 36.1%. No control group; many patients also received conventional treatment. Largest real-world dataset to date, but hypothesis-generating only.

  • Cedars-Sinai Phase I/II (ASCO 2025) — Ivermectin + Balstilimab in Metastatic TNBCActive Trial

    Ongoing. First prospective human trial combining ivermectin with immunotherapy in breast cancer. Results pending — one of the most important studies to watch in 2026.

🔬 What This Means for PatientsThe mebendazole RCT (2022) is the most meaningful human data in this space and is genuinely encouraging. The observational data from the Hulscher study is the largest real-world dataset so far, but without a control group it cannot prove causation. The ivermectin-specific human trials are still early. This is a rapidly evolving area — not settled science, but not fringe either.

5. Reported Patient Outcomes


The following cases were shared publicly via Dr. Makis's Substack and X posts (2024–2026). They are anonymized self-reported accounts. These are anecdotal reports, not clinical trial data. They cannot be used to predict outcomes for any individual patient, and they have not been independently verified.

We include them here because they are part of the public discussion — but we urge readers to weigh them appropriately, as case selection bias (reporting only successes) is a significant concern with this type of evidence.
1

53-year-old woman, Stage 2 TNBC (7.8 cm tumor) — Reported cancer-free after 7 months (December 2024–July 2025)

Cannot confirm: concurrent treatments, staging accuracy, verification of NED status

2

58-year-old, Recurrent Stage 4 Kidney Cancer — Reported dying tumors within 10 weeks

Tumor dying ≠ remission. Definition of outcome not independently verified.

3

70-year-old man, Stage 4 Lymphoma — Reported complete remission in 2.5 months

Lymphoma response rates vary widely; spontaneous remission is also documented in some lymphoma types.

4

39-year-old woman, Stage 4 Colon with liver mets — CEA marker dropped from 441 to 21.9 over 4 months

CEA reduction is meaningful and measurable, though not confirmed by imaging in this report.

5

83-year-old, Stage 3 Follicular Lymphoma — Near-total remission reported at 6 months on 1 mg/kg/day

Follicular lymphoma is naturally indolent; watchful waiting alone can produce remission. Confounding is possible.

⚠ Critical Caveat on Case ReportsDr. Makis's claimed overall response rate of 65–70% in Stage 4 patients is based on self-selected, self-reported cases shared on social media — not a prospectively enrolled, independently verified cohort. Failures and non-responders are less likely to be shared publicly. This does not mean the results are fabricated, but it does mean they cannot be taken at face value without independent validation.

6. Risks, Side Effects & Drug Interactions


Ivermectin has a well-established safety profile at standard antiparasitic doses. At the high doses used in the Makis protocol, the risk picture changes and must be managed actively with a physician.
  • Neurotoxicity: High-dose ivermectin can cross the blood-brain barrier, particularly in patients with certain genetic variants (ABCB1/P-glycoprotein mutations). Symptoms can include dizziness, confusion, vision changes, or seizures.
  • Hepatotoxicity: Liver enzyme elevation is possible, especially when combined with high-dose benzimidazoles. Liver function tests every 4–6 weeks are essential.
  • Drug interactions: Ivermectin interacts with warfarin, certain immunosuppressants, CNS depressants, and CYP3A4-metabolized drugs (including many chemotherapy agents). Full medication review is mandatory.
  • GI side effects: Nausea, diarrhea, and abdominal discomfort are reported in approximately 25% of patients at high doses, per the Hulscher et al. observational study.
  • Unknown long-term safety: There is no long-term human safety data for continuous high-dose ivermectin (months to years). Claims that 2 mg/kg/day is "extremely safe" are not supported by completed long-term studies.
  • Delay of proven treatment: For patients with cancers that have well-established effective treatments (e.g., early-stage breast cancer, certain lymphomas, testicular cancer), delaying conventional therapy to pursue repurposed drugs carries significant risk.

Monitoring Recommended

Any physician supervising this protocol should track: complete blood count (CBC), comprehensive metabolic panel (CMP) including liver and kidney function, tumor markers where applicable, and imaging at regular intervals. Any symptom of neurotoxicity requires immediate dose reduction or cessation.

7. How to Access Ivermectin Safely

Quality and sourcing matter significantly. Veterinary-grade ivermectin formulations (pastes, liquids) have inconsistent concentrations and are not designed for human pharmacokinetics. For anyone considering this protocol, pharmaceutical-grade human tablets are the only appropriate form, and a physician prescription is the appropriate access route.

✅ Key Principles for Safe SourcingOnly use human pharmaceutical-grade 12 mg tablets. Obtain via a licensed physician's prescription. Avoid online sources that do not require a prescription — these are unregulated. Ensure the compounding pharmacy, if used, is US-licensed and follows Good Manufacturing Practice (GMP) standards.

Ivermectin + Mebendazole — Physician-Prescribed Access

The Wellness Company offers a physician-prescribed, pharmacy-compounded ivermectin and mebendazole formula — reviewed by Dr. Peter McCullough. Standardized dosing (25 mg ivermectin + 250 mg mebendazole), quality-tested, and dispensed through US-licensed compounding pharmacies.

View Ivermectin + Mebendazole Formula →

⚠ Affiliate link. This is not a replacement for oncology care. Consult your physician before use. Individual results vary. This product is not FDA-approved to treat cancer.

8. Frequently Asked Questions

Can I take ivermectin alongside my chemotherapy?

Potentially, but only under physician supervision. Ivermectin interacts with several chemotherapy drugs via the CYP3A4 pathway. Some combinations (like with balstilimab, tested at Cedars-Sinai) appear to be under active study. Do not add ivermectin to your regimen without telling your oncologist, as it may affect drug levels and safety.
Is ivermectin FDA-approved to treat cancer?
No. Ivermectin is FDA-approved only for antiparasitic indications (onchocerciasis, strongyloidiasis, scabies, head lice). Its use in cancer is entirely off-label and investigational. This does not mean it cannot be prescribed — physicians can legally prescribe off-label — but it does mean no regulatory body has reviewed cancer-specific safety and efficacy data.
How is ivermectin different from fenbendazole for cancer?
Both are antiparasitic drugs with overlapping proposed mechanisms (microtubule disruption, metabolic interference). Fenbendazole (a benzimidazole) has more published human case reports, partly due to the Joe Tippens story. Ivermectin has more varied proposed mechanisms including immune modulation. Dr. Makis's approach combines both to target multiple pathways simultaneously. They are used together precisely because they appear to work differently and may be synergistic.
Should I use veterinary ivermectin to save money?
No. Veterinary formulations (ivermectin paste, livestock pour-on solutions) contain excipients not intended for humans, have inconsistent and hard-to-measure concentrations, and carry real toxicity risks. Human pharmaceutical-grade tablets are the only appropriate form for human use.
What does "No Evidence of Disease" (NED) actually mean?
NED means that currently available imaging and lab tests show no detectable cancer. It is not the same as being cured — cancer can return after NED. It is, however, a meaningful clinical milestone. When case reports claim NED, it is worth asking: was this confirmed by PET/CT or MRI? By which physician? How long has NED been maintained?
My oncologist won't discuss ivermectin. What should I do?
This is a real and frustrating situation for many patients. Seeking a second opinion from an integrative oncologist — a physician who works with both conventional and complementary approaches — can be helpful. Physicians affiliated with organizations like FLCCC or integrative oncology programs at academic centers may be more open to discussing repurposed drugs. Be transparent with all your physicians about everything you are taking.

Key Takeaways

Ivermectin's anti-cancer potential is a legitimate area of scientific interest, supported by preclinical data and some early human studies — particularly for mebendazole in colorectal cancer. It is not an established cancer treatment, and the gap between promising lab results and proven clinical benefit is significant and not yet bridged.

Dr. Makis has made this space more visible and has given hope to many patients who feel conventional medicine has run out of options. His case reports are numerous and some are striking. But hope must be held alongside honesty: these are not controlled data, outcomes may be influenced by concurrent conventional treatment, and failures are underreported.

For cancer patients considering this path: Work with a physician. Monitor your labs. Do not abandon effective conventional treatments. Understand the difference between what the evidence shows and what it suggests. Ask hard questions — of your oncologist and of advocates for repurposed drugs alike.

References & Further Reading

  1. Juarez M et al. (2020). Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug. PLOS ONE.
  2. Elayapillai SP et al. (2021). Ivermectin inhibits growth and induces apoptosis of human ovarian cancer cells. International Journal of Oncology.
  3. Pinto-Díez C et al. (2022). Mebendazole plus FOLFOX4/bevacizumab in Stage 4 colorectal cancer. Life Sciences. doi:10.1016/j.lfs.2022.120522
  4. Sepulveda-Arias JC et al. (2022). Mebendazole + temozolomide in high-grade glioma. EClinicalMedicine. PubMed
  5. Hulscher et al. (April 2026). Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer — Observational Cohort (197 patients). Preprint/publication.
  6. Yuan Yuan et al. (ASCO 2025). Phase I/II: Ivermectin + balstilimab in metastatic triple-negative breast cancer. Cedars-Sinai Medical Center.
  7. Makis W. Substack @MakisMD — Protocol updates and patient case reports (2023–2026).

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiation. Access to modern cancer care also remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings may face significant barriers to timely diagnosis and access to cutting-edge treatments. In this context, repurposed drugs—including ivermectin—are sometimes discussed in research and public discourse due to their low c...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Dr. William Makis, a radiologist and cancer researcher, has developed a "hybrid orthomolecular" protocol that incorporates ivermectin as a repurposed drug for cancer treatment. This approach targets cancer stem cells and mitochondrial dysfunction, often in combination with other therapies like benzimidazoles (e.g., mebendazole or fenbendazole), vitamins, and dietary changes. The protocol is based on preclinical studies, case reports, and his clinical observations, but it remains experimental and unapproved by regulatory bodies like the FDA for cancer use. Dosages are weight-based (e.g., for a 70 kg/154 lb person, 1 mg/kg = 70 mg) and stratified by cancer severity: low-grade (early-stage or slow-growing), intermediate-grade (moderately progressive), or high-grade (aggressive, metastatic, or "turbo" cancers). Always consult a healthcare provider for personalization, monitoring (e.g., liver/kidney function), and integration with conventional treatments. Key Ivermectin...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146 (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer ( J Clin Oncol 2025 ) Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balsti...
Read more

Archive

Show more